Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
WordPress Malware Uses Ethereum to Evade Removal 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
 - EconoTimes)
Add as a preferred source on Google
NEW ORLEANS, March 03, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (NYSE:NVO), if they purchased the Company’s American Depository Receipts (“ADRs”) between the expanded period of February 5, 2015 and October 27, 2016, inclusive (the “Class Period”). The action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017.
About the Lawsuit
Novo Nordisk and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 5, 2016, the Company announced disappointing earnings for the 2016 second quarter. Then, on October 28, 2016, the Company disclosed that it was cutting its long-term profit growth by 50% and that it had received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products.
On this news, the price of Novo Nordisk’s ADRs plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
